Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28136543 | 0.79 | SPHK2 (0.35) | SPHK2SPHK1CETP | |
| SCHEMBL16597197 | 0.78 | PLA2G1B (0.37) | — | |
| SCHEMBL25058928 | 0.77 | SPHK2 (0.40) | SPHK2SPHK1CETP | |
| SCHEMBL15750870 | 0.76 | LMNA (0.40) | SPHK2SPHK1CETP | |
| SCHEMBL4145583 | 0.73 | LMNA (0.48) | SPHK2SPHK1CETP | |
| SCHEMBL20422714 | 0.73 | LMNA (0.52) | — | |
| SCHEMBL5998810 | 0.73 | LMNA (0.52) | — | |
| SCHEMBL8780310 | 0.71 | TSHR (0.35) | — | |
| SCHEMBL20243272 | 0.70 | TSHR (0.36) | — | |
| SCHEMBL11213426 | 0.70 | SPHK2 (0.35) | SPHK2SPHK1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001947-A1 | DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-7635701-B2 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2009-12-22 | — | — | US | disclosed |
| EP-1819332-B1 | PYRROLOPYRIDINE-2-CARBOXYLIC ACID AMIDES | PROSIDION LTD (GB) | 2009-03-11 | — | — | EP | disclosed |
| US-20060293354-A1 | Pyrimidine derivatives and their use as CB2 modulators | GLAXO GROUP LIMITED (GB) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293354-A1 | Pyrimidine derivatives and their use as CB2 modulators | CNR2, CNR1, P2RX3 | SPHK2 178/4885SPHK1 288/4885CETP 3256/4885 |
| US-20170001947-A1 | DIETHER BASED BIODEGRADABLE CATIONIC LIPIDS FOR siRNA DELIVERY | NR1H4, LDLR, LIPA | SPHK2 551/4885SPHK1 713/4885CETP 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.